Velcade Podcasts This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Trial Updates At ASCO: Approval Of Daratumumab In Combination With Revlimid Or Velcade & Dexamethasone
Robert Rifkin MD Of US Oncology Research Discusses Trial Updates At ASCO: Approval Of Daratumumab In Combination With Revlimid Or Velcade & Dexamethasone. Author: Annual-Meeting Added: 06/06/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 6, 2019 Category: Cancer & Oncology Source Type: podcasts

Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.
Katja Weisel from the University Medical Center Hamburg-Eppendorf discusses the efficacy and safety of daratumumab, bortezomib, and dexamethasone.<br /><br />Background: MM patients (pts) with high cytogeneti... Author: Annual-Meeting Added: 06/05/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 5, 2019 Category: Cancer & Oncology Source Type: podcasts

Daratumumab Phase 3 Study: Phase 3 Randomized Study Of Daratumumab + Bortezomib:Thalidomide:Dexamethasone (D-VTd) VS VTd In Transplant-Eligible NDMM
Philippe Moreau, MD Of Nantes Faculty of Medicine Discusses Daratumumab Phase 3 Study: Phase 3 Randomized Study Of Daratumumab + Bortezomib:Thalidomide:Dexamethasone (D-VTd) VS VTd In Transplant-Eligi... Author: Annual-Meeting Added: 06/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 3, 2019 Category: Cancer & Oncology Source Type: podcasts

ISA Combo: Velcade, Revlimid & Dexamethasone
Joanne Lager, M.D. Head of Oncology Development, Sanofi Discusses ISA Combo: Velcade, Revlimid & Dexamethasone At The 60th ASH Annual Meeting on Dec 1, 2018. Author: ASHReport Added: 12/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 18, 2018 Category: Cancer & Oncology Source Type: podcasts

Subcutaneous daratumumab: an update on the latest MM clinical trials
Previous clinical trial investigations have established that daratumumab plus bortezomib, melphalan and prednisone, also known as dara+VMP, is significantly more effective than VMP alone in terms of r... Author: VJHemOnc Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts

Maintenance therapy for MRD negativity in MM
The RVD chemotherapy regimen combines lenalidomide, bortezomib, and dexamethasone, and is recognized by the European Society for Medical Oncology in its guidelines as the current standard therapy for ... Author: VJHemOnc Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts

Adding to Lenalidomide to Make it Work Better Prednisone inhibitors, carfilzomib, and bortezomib
Paul G. Richardson, MD, explains Adding to Lenalidomide to Make it Work Better Prednisone inhibitors, carfilzomib, and bortezomib at Imedex Great Debates 2018. Author: hematologydebates Added: 05/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 10, 2018 Category: Cancer & Oncology Source Type: podcasts

RVD-Lite Mission Treating Over 50 Patients Regimen of Bortezomib, lenalidomide, steroids
Paul G. Richardson, MD, explains RVD-Lite Mission Treating Over 50 Patients Regimen of Bortezomib, lenalidomide, steroids at Imedex Great Debates 2018. Author: hematologydebates Added: 05/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 10, 2018 Category: Cancer & Oncology Source Type: podcasts

Venetoclax Shown Great Results with Bortezomib It targets 11;14, oral, well-tolerated
Paul G. Richardson, MD, explains Venetoclax Shown Great Results with Bortezomib It targets 11;14, oral, well-tolerated at Imedex Great Debates 2018. Author: hematologydebates Added: 05/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 8, 2018 Category: Cancer & Oncology Source Type: podcasts

CASTOR trial update: daratumumab/bortezomib/dexamethasone is an important regimen for R/R MM
An exciting update on the CASTOR trial was presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA. Here, Katja Weisel, MD, of University of Tbin... Author: VJHemOnc Added: 04/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 20, 2018 Category: Cancer & Oncology Source Type: podcasts

VCDI for multiple myeloma: an update
VCD (bortezomib, cyclophosphamide and dexamethasone) is an effective chemotherapy combination commonly used for the treatment of newly diagnosed multiple myeloma (MM), while bortezomib combined with i... Author: VJHemOnc Added: 02/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 6, 2018 Category: Cancer & Oncology Source Type: podcasts

Developments of Phase 3 Trial: BOSTON Bortezomib in combination with Selinexor for treating Myeloma
Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses developments of Phase 3 trial: BOSTON - Bortezomib in combination with Selinexor for treating myeloma at the 2017 American Socie... Author: ASHReport Added: 01/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 22, 2018 Category: Cancer & Oncology Source Type: podcasts

High-Response Rates from both Selinexor and Velcade The combination of the two show synergy against Myeloma
Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses high-response rates from both Selinexor and velcade and the combination of the two show synergy against myeloma at the 2017 Amer... Author: ASHReport Added: 01/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Vs VMP in NDMM Pts (ALCYONE)
Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) ... Author: InternationalMyelomaFoundation Added: 01/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Selinexor in Combination with SVd Induces a High Response Rate in Patients with RMM
Selinexor in Combination with Weekly Low Dose Bortezomib and Dexamethasone (SVd) Induces a High Response Rate with Durable Responses in Patients with Refractory Multiple Myeloma (MM)<br /><br />Nizar J. Bahli... Author: InternationalMyelomaFoundation Added: 01/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 16, 2018 Category: Cancer & Oncology Source Type: podcasts